February 9, 2021
St. John’s University’s College of Pharmacy and Health Sciences, in collaboration with Relmada Therapeutics, Inc., is proud to announce a new fellowship for pharmacy program graduates. The St. John’s University/Relmada Pharmaceutical Industry Fellowship in Clinical Development—Major Depressive Disorders (MDD) is a one- or two-year postgraduate experience for individuals who have earned a doctor of pharmacy degree.
“Relmada Therapeutics, Inc. is on the cutting edge of research and has a growing team with decades of drug development experience at all stages,” said Joseph M. Brocavich, Pharm.D., Senior Associate Dean for Pharmacy and Associate Clinical Professor, College of Pharmacy and Health Sciences. “This new fellowship is an excellent learning and research opportunity for graduates seeking extensive experience in clinical development.”
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules.
“We are excited to partner with St. John’s on this important fellowship program as we advance REL-1017 for the treatment of MDD, a major unmet medical need,” said Maged S. Shenouda ’88P, Chief Financial Officer, Relmada Therapeutics. “Relmada’s passion for excellence and the superb quality of St. John’s Doctor of Pharmacy program are a powerful combination.”
The overall objective of the fellowship is to provide hands-on experience in the clinical development of special population clinical studies (Phase 1) and late phase (Phase 3) clinical studies to support the filing of a new drug application (NDA) for a MDD pharmaceutical. The fellowship combines clinical development experience with broader exposure to areas such as regulatory, quality assurance, nonclinical, and CMC (chemistry, manufacturing, and controls), to introduce and develop valuable skills in the overall NDA pathway.
Fellows will use their skills to make a positive impact on the advancement of a therapeutic candidate for the treatment of MDD. The fellowship involves establishing strong working relationships with health economics and outcomes research, medical affairs, regulatory affairs, quality assurance, and clinical development activities.